Metabolic & Weight Management
Tirzepatide
Also known as Mounjaro · Zepbound
Clinically studiedSubcutaneous injectionFDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea). Carries a boxed warning for thyroid C-cell tumor risk seen in rodents.
Tirzepatide is a single molecule that activates receptors for two incretin hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. This dual action improves glucose-dependent insulin response, slows gastric emptying, and reduces appetite. It was the first approved dual GIP/GLP-1 receptor agonist.
Studied / used for
- studied for glycemic control in type 2 diabetes
- studied for chronic weight management in obesity/overweight
- studied for moderate-to-severe obstructive sleep apnea with obesity
Commonly reported side effects
- nausea
- diarrhea
- vomiting
- constipation
- abdominal pain
- decreased appetite
- injection-site reactions
Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.
Not medical advice.
This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.